



# The Role of Ischemia Reversal Program and Dietary Restriction in Improving Quality of Life by Reducing Myocardial Ischemia and Risk of Heart Disease

Yogita Patil <sup>a++\*</sup> and Bipin Gond <sup>b#</sup>

<sup>a</sup> Madhavbaug Clinic - Virar West, Maharashtra, India.

<sup>b</sup> Madhavbaug Clinics, Western Mumbai, Marathwada, Madhya Pradesh and Delhi NCR Zone, India.

## **Authors' contributions**

*This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.*

## **Article Information**

### **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/99493>

**Original Research Article**

**Received: 04/03/2023**

**Accepted: 09/05/2023**

**Published: 05/07/2023**

## **ABSTRACT**

**Background:** Curbing the prevalence rates of ischemia heart disease presents a formidable challenge owing to a complex interplay of determinants such as low diagnostic rates, poor patient medication adherence, and less practice of evidence-based interventions. Ischemia Reversal Program (IRP) is an alternative therapy for ischemic heart disease patients, it is a combination of *Panchakarma* and allied therapy. The study intended to assess the role of IRP in improving quality of life by reducing myocardial ischemia and risk of heart disease.

**Methods:** A prospective, observational, single-centre study was conducted at Madhavbaug Cardiac Care Clinic from March 2021 to December 2022. Patients aged 18 years and above diagnosed with

<sup>++</sup> Clinic Head;

<sup>#</sup> ZMH of Western;

\*Corresponding author: Email: [yogita.gharat16@gmail.com](mailto:yogita.gharat16@gmail.com);

ischemic heart disease and that had participated in the IRP for a minimum of 7 sessions over a 90-day duration were included in this study. Data at baseline was compared with data at the 90-day follow-up.

**Results:** Of the 35 patients screened, 23 patients were included in the present study. Mean age of the study patients was  $55.30 \pm 8.01$  years and 78.3% were male. The  $VO_2$  peak significantly improved from  $17.53 \pm 9.17$  on day 1 to  $26.93 \pm 7.71$  at day 90.

**Conclusion:** The IRP can be an effective treatment to reduce risk of mortality due to heart disease and to improve quality of life in stable ischemic heart disease patients.

**Keywords:** Ayurveda; coronary artery disease; ischemic heart disease; Panchakarma;  $VO_2$  peak.

## 1. INTRODUCTION

Ischemic heart disease is one of the foremost causes of morbidity and mortality in adults in India. This disease is accountable for 1.5 million deaths with a mortality rate of 109.23 deaths per 100,000 population in 2019. This also contributed to 7.79% of the total disability-adjusted life years (DALYs). This disease greatly affects the working population, thereby impacting the economic status of the country [1].

Pharmacotherapy remains the cornerstone treatment for ischemic heart disease patients. Drugs belonging to classes of angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers (CCB), and beta-blockers (BB) have been implemented in the treatment strategy of these ischemic heart disease patients as well as ischemic heart disease patients with hypertension as an underlying comorbidity [2]. However, low diagnostic rates, poor patient medication adherence, and less practice of evidence-based interventions spur an increase in healthcare expenditure [3]. The World Health Organization has estimated 237 million US dollars direct health care expenditure to be incurred by India due to indirect loss of productivity due to ischemic heart disease [4]. Hence, the need to explore alternative therapeutic interventions for ischemic heart disease.

The Ayurvedic practice of medicine, a traditional healing practice originating in India accentuates the use of herbs, minerals, and medicinal plants to address various health conditions, including those in acute phase of disease. The medications are often prepared based on the patient-specific needs and doshas as per Ayurveda principles [5]. *Panchakarma* along with adjunct allopathic medication is used by Ayurvedic physicians. The IRP is a combination of *Panchakarma* and allied therapy. Against this background, this study intended to assess the

role of IRP in improving quality of life by reducing myocardial ischemia and risk of heart disease.

## 2. MATERIALS AND METHODS

### 2.1 Study Design and Patient Population

A prospective, observational, single-centre study was conducted at Madhavbaug Cardiac Care Clinic from March 2021 to December 2022. Patients aged 18 years and above, regardless of gender diagnosed with ischemic heart disease who had participated in the Ischemia Reversal Program (IRP) for a minimum of 7 sessions over a 90-day duration were included in this study. The study conformed to the principles of Good Clinical Practice [6] and the Declaration of Helsinki [7]. Patients were enrolled after written informed consent was obtained.

### 2.2 Ischemia Reversal Program

The IRP is a 3-step procedure which was initiated after patients consumed a light breakfast. One session lasted 60–75 mins. The first procedure was *Snehana* which was external oleation through centripetal upper strokes directed towards the heart. The herbs used were 100 ml of 80% sesame oil and 20% lavender oil. The duration of this procedure was 30–35 mins. The second procedure was *Swedana* which was passive heat therapy using Dashmoola i.e. a group of 10 herbal roots with steam at less than  $40^\circ$  C. The duration of this procedure was 10–15 mins with 3–4 mins of relaxation after the procedure. The third procedure was *Basti* which was per rectal drug administration using a rectal solution. 100 ml luke-warm decoction of Gokshura (*Tribulus terrestris*), Haridra (*Curcuma longa*), and Amalaki (*Emblica officinalis*) was used. The duration of this procedure was 15 mins. The patients adhered to 1200 calories/day intake.

## 2.3 Cardiac Stress Test

Cardiac stress testing was done following the Modified Bruce Protocol. Their maximum work load was assessed in terms of metabolic equivalents (METs) and this was multiplied by 3.5 to give  $VO_2$  peak.

## 2.4 Data Collection

On day 1 of the IRP program, a detailed patient history was documented. Anthropometric measurements,  $VO_2$  peak was also recorded as per international standards [8]. These details were again recorded on day 90 of the IRP program. Data of day 1 was compared with data of day 90. Data of only those patients who had complete data for 90 days was included in this analysis.

## 2.5 Statistical Analysis

Categorical data are expressed as number (percentage) and continuous data are expressed as mean  $\pm$  standard deviation. Paired t-test was used to determine the difference between baseline and the 90-day follow-up. R version 3.4.2 software was used to analyse the data.

## 3. RESULTS

### 3.1 Demographics, Anthropometric Measurements and Laboratory Investigations

A total of 35 patients were screened, however only 23 patients completed the stress test and hence were included in the study. Mean age of the study patients was  $55.30 \pm 8.01$  years. Of the 23 patients, 18 (78.3%) were male. Weight decreased from  $67.53 \pm 11.11$  kg to  $62.95 \pm 8.36$  kg ( $p < 0.001$ ). Body mass index decreased from  $26.42 \pm 4.21$  to  $24.60 \pm 3.18$  ( $p < 0.001$ ). Abdomen girth decreased from  $99.50 \pm 10.90$  cm to  $94.00 \pm 8.24$  cm ( $p < 0.001$ ). Systolic and diastolic blood pressure decreased from  $132.26 \pm 17.71$  mmHg to  $118.78 \pm 9.68$  ( $p < 0.001$ ) and  $84.61 \pm 11.34$  mmHg to  $78.00 \pm 7.20$  mmHg ( $p < 0.001$ ), respectively.  $VO_2$  peak increased from  $17.53 \pm 9.17$  to  $26.93 \pm 7.71$  ( $p < 0.001$ ). MET value increased from  $4.91 \pm 2.64$  to  $7.73 \pm 2.12$  ( $p < 0.001$ ). The details of the demographics, anthropometric measurements and laboratory

investigations of the study patients at baseline and follow-up is detailed in Fig. 1.

### 3.2 Impact of Ischemia Reversal Program on Weight

Weight decreased for the 56–90 years age group (day 1:  $67.31 \pm 13.03$  kg and day 90:  $61.67 \pm 10.00$  kg, percent change: -8.37%), males (day 1:  $69.38 \pm 8.74$  kg and day 90:  $64.46 \pm 6.04$  kg, percent change: -7.10%), and low-risk patients according to  $VO_2$  peak (day 1:  $70.71 \pm 10.93$  kg and day 90:  $64.81 \pm 6.57$  kg, percent change: -5.90%). The impact of the IRP on weight of study patients is demonstrated in Table 1.

### 3.3 Impact of Ischemia Reversal Program on Body Mass Index

Body mass index decreased for the 56–90 years age group (day 1:  $26.69 \pm 4.84$  and day 90:  $24.36 \pm 3.39$ , percent change: -8.76%), males (day 1:  $26.01 \pm 3.07$  and day 90:  $24.15 \pm 2.21$ , percent change: -7.17%), and low-risk patients according to  $VO_2$  peak (day 1:  $26.65 \pm 3.61$  and day 90:  $24.47 \pm 1.86$ , percent change: -8.19%). The impact of the IRP on body mass index of study patients is demonstrated in Table 2.

### 3.4 Impact of Ischemia Reversal Program on Abdomen Girth

Abdomen girth decreased for the 56–90 years age group (day 1:  $101.18 \pm 13.35$  cm and day 90:  $94.45 \pm 9.27$  cm, percent change: -6.65%), males (day 1:  $98.75 \pm 7.67$  cm and day 90:  $93.17 \pm 6.34$ , percent change: -5.65%), and low-risk patients according to  $VO_2$  peak (day 1:  $99.75 \pm 9.39$  and day 90:  $93.63 \pm 6.08$ , percent change: -6.14%). The impact of the IRP on abdomen girth of study patients is demonstrated in Table 3.

### 3.5 Impact of Ischemia Reversal Program on $VO_2$ Peak

$VO_2$  peak increased for the 56–90 years age group (day 1:  $16.89 \pm 9.86$  and day 90:  $27.17 \pm 8.37$ , percent change: 60.90%), males (day 1:  $18.23 \pm 9.92$  and day 90:  $28.86 \pm 6.97$ , percent change: 58.25%), and low-risk patients according to  $VO_2$  peak (day 1:  $28.54 \pm 6.18$  and day 90:  $33.82 \pm 4.53$ , percent change: 18.52%). The impact of the IRP on  $VO_2$  peak of study patients is demonstrated in Table 4.




Fig. 1. Demographics, anthropometric measurements and laboratory investigations at baseline and follow-up

Table 1. Impact of Ischemia Reversal Program on weight

Variable	Weight (kg) Day 1 n=23	Weight (kg) Day 90 n=23	Change (%)
<b>Age, years</b>			
25–55	67.73 ± 9.01	64.13 ± 6.28	-5.32
56–90	67.31 ± 13.03	61.67 ± 10.00	-8.37
<b>Gender</b>			
Male	69.38 ± 8.74	64.46 ± 6.04	-7.10
Female	60.84 ± 15.37	57.54 ± 12.36	-5.42
<b>VO<sub>2</sub> peak</b>			
Low-risk	70.71 ± 10.93	64.81 ± 6.57	-5.90
Intermediate-risk	70.19 ± 10.17	65.99 ± 6.03	-4.20
Severe-risk	62.01 ± 9.92	58.44 ± 9.71	-3.58

All data are expressed as mean ± standard deviation

Table 2. Impact of Ischemia Reversal Program on body mass index

Variable	Body mass index Day 1 n=23	Body mass index Day 90 n=23	Change (%)
<b>Age, years</b>			
25–55	26.18 ± 3.52	24.28 ± 2.95	-5.19
56–90	26.69 ± 4.84	24.36 ± 3.39	-8.76
<b>Gender</b>			
Male	26.01 ± 3.07	24.15 ± 2.21	-7.17
Female	27.91 ± 6.69	26.22 ± 5.05	-6.06
<b>VO<sub>2</sub> peak</b>			
Low-risk	26.65 ± 3.61	24.47 ± 1.86	-8.19
Intermediate-risk	28.42 ± 5.22	26.65 ± 3.70	-6.23
Severe-risk	24.45 ± 2.58	22.94 ± 2.68	-6.21

All data are expressed as number (percentage) or mean ± standard deviation.

**Table 3. Impact of Ischemia Reversal Program on abdomen girth**

Variable	Abdomen girth Day 1 n=23	Abdomen girth Day 90 n=23	Change (%)
<b>Age, years</b>			
25–55	97.96 ± 7.70	93.58 ± 7.15	-4.47
56–90	101.18 ± 13.35	94.45 ± 9.27	-6.65
<b>Gender</b>			
Male	98.75 ± 7.67	93.17 ± 6.34	-5.65
Female	102.2 ± 18.03	97.0 ± 12.51	-5.09
<b>VO<sub>2</sub> peak</b>			
Low-risk	99.75 ± 9.39	93.63 ± 6.08	-6.14
Intermediate-risk	102.57 ± 14.39	96.29 ± 10.55	-6.13
Severe-risk	96.56 ± 7.44	92.38 ± 7.31	-4.34

All data are expressed as number (percentage) or mean ± standard deviation.

**Table 4. Impact of Ischemia Reversal Program on VO<sub>2</sub> peak**

Variable	VO <sub>2</sub> peak Day 1 n=23	VO <sub>2</sub> peak Day 90 n=23	Change (%)
<b>Age, years</b>			
25–55	18.11 ± 8.45	26.72 ± 7.05	47.53
56–90	16.89 ± 9.86	27.17 ± 8.37	60.90
<b>Gender</b>			
Male	18.23 ± 9.92	28.86 ± 6.97	58.25
Female	14.97 ± 4.92	20.02 ± 6.12	33.72
<b>VO<sub>2</sub> peak</b>			
Low-risk	28.54 ± 6.18	33.82 ± 4.53	18.52
Intermediate-risk	14.45 ± 1.69	26.45 ± 6.22	12.00
Severe-risk	9.21 ± 1.60	20.48 ± 5.23	11.27

All data are expressed as mean ± standard deviation.

#### 4. DISCUSSION

Ischemic heart disease prevalence has increased significantly throughout the years such that it has become epidemic. The IRP has been designed to improve blood flow to the heart and increase tolerance levels to improve quality of life. It is associated with significant improvements in VO<sub>2</sub> peak leading to better prognosis in ischemic heart disease patients [2]. A study published in 2018 [9] sought to investigate the efficacy of IRP on VO<sub>2</sub> peak as an adjunctive therapy to standard anti-ischemic therapy in patients with ischemic heart disease patients. Study findings revealed VO<sub>2</sub> peak significantly increased from 20.29 ± 6.72 to 29.40 ± 6.7. At baseline 50% patients were at moderate risk and 31.6% were at high risk which significantly improved to 47.4% moderate risk and 52.6% at low risk. Dependency on adjunctive medication

also deterred. These findings are in line with findings of the current study.

Hypertension is one of the predominant risk factors of ischemic heart disease. According to the World Health organization, hypertension is accountable for 16% ischemic heart disease related deaths [2] with cardiovascular risk mortality increasing from blood pressure as low as 110/70 mmHg [10]. Thus, maintaining blood pressure values within normal ranges remains the cornerstone of both primary and secondary ischemic heart disease prevention. Maintaining blood pressure of 140/90 mmHg is recommended for primary prevention, while values of 130/85 mmHg is recommended for secondary prevention [11]. A study published in 2018 [2] sought to evaluate the VO<sub>2</sub> peak and Duke treadmill score on IRP on ischemic heart patients with hypertension. It also sought to

assess the effect of IRP on blood pressure.  $VO_2$  peak significantly increased from  $20.74 \pm 7.25$  to  $29.69 \pm 6.62$ . Moreover, there was a decrease in the number of moderate and high-risk patients at the 90-day follow-up. Systolic and diastolic blood pressure significantly decreased from  $127.68 \pm 13.65$  mmHg to  $122.74 \pm 11.65$  mmHg and from  $78.95 \pm 7.37$  mmHg to  $75.78 \pm 6.92$  mmHg, respectively. Moreover, a recently published study with a similar aim [4] observed significant improvement in Duke treadmill score from  $-1.76$  to  $6.34$ . This further fortifies our findings.

Over the past two decades, obesity has emerged as a global public health concern affecting both children and adults. Several studies have revealed obesity as an independent risk factor for cardiovascular disease [12]. Moreover, several large prospective studies assessed the association between obesity and coronary heart disease and revealed a 40% increase in mortality for every  $5 \text{ kg/m}^2$  increase in body mass index above  $25 \text{ kg/m}^2$  [13]. Adipokines released by adipose tissue can induce endothelial dysfunction, systemic inflammation, and insulin resistance – all these contribute towards the risk of atherosclerosis [14-16]. The IRP has also been assessed in the subgroup of obese patients. The study [9] sought to understand the role of low carbohydrate diet and Ayurveda based IRP in management of ischemic heart disease with obesity. Obese patients were defined as those with body mass index  $\geq 30 \text{ kg/m}^2$ . The  $VO_2$  peak increased significantly from  $17.82 \pm 7.23$  on day 1 to  $26.65 \pm 6.14$  at day 90.

The Ischemia Reversal Program (IRP) is a combination of *Panchakarma* and allied therapy. This therapy has been assessed in ischemic heart disease patients including those with underlying comorbidities such as hypertension and obesity.

## 5. STUDY LIMITATIONS

The study has a few limitations that deserve mention. Firstly, the small sample size due to which the study findings cannot be generalized. Secondly, this was a single arm study, a comparator arm of standard therapy might have provided further insights. Thirdly, a longer follow-up duration might have provided insights into the long-term outcomes of the IRP.

## 6. CONCLUSION

The Ischemia Reversal program can be effective treatment to reduce risk of mortality due to heart

disease and to improve quality of life in stable ischemic heart disease patients.

## CONSENT

As per international standard or university standard, patient(s) written consent has been collected and preserved by the author(s).

## ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

## ACKNOWLEDGEMENTS

Dr. Rahul Mandole Head of the Research Department gave guidance and support and Miss Pallavi Mohe from the Research Department of Madhavbaug Cardiac Care Clinics took all the efforts for data collection and Analysis.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Bhattacharjee S, Yaghmaei N, Phuong CTL, Neupane D. Factors influencing the readiness to tackle the burden of ischaemic heart disease in India: a systematic review protocol. *BMJ Open*. 2021;11(8):e047464.
2. Sane R, Gond B, Raje G, Walzade K, Badre A, Mandole R. Ischemia Reversal Program (IRP) in patients suffering from Ischemic Heart Disease (IHD) with known history of Hypertension: A Retrospective Study. *J Ayurveda Med Sci*. 2018;3(2): 377–83.
3. O'Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers: Challenges for physicians, payers, and policy makers. *Arch Intern Med*. 2006;166(17):1802–4.
4. Sane R, Sugwekar V, Nadapude A, Hande A, Depe G, Mandole R. Study of efficacy of ischemia reversal program (IRP) in ischemic heart disease (IHD) patients with  $VO_{2max}$  and Duke's treadmill score. *Int J Basic Clin Pharmacol*. 2018;7(8):1642.
5. Pandey MM, Rastogi S, Rawat AKS. Indian traditional ayurvedic system of medicine and nutritional supplementation. *Evid*

- Based Complement Alternat Med. 2013; 2013: 376327.
6. Dixon JR. Jr The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998;6:65–74.
  7. General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014 Summer; 81(3):14–8.
  8. Lairikyengbam SKS, Davies AG. Interpreting exercise treadmill tests needs scoring system. BMJ. 2002;325(7361):443.
  9. Sane R, Wadekar A, Shinde K. Understanding the role of Ayurveda based ischemia reversal program and low carbohydrate diet in reduction of risk of heart disease. Asian Journal of Cardiovascular Research. 2019;2(1):1–8.
  10. Sarbere L, Khan S, Sarbere P. Efficacy of ischemic reversal program in stable ischemic heart disease patients to improve quality of life. Asian Journal of Cardiovascular Research. 2023;8(3):6–11.
  11. Špinar J. Hypertension and ischemic heart disease. Cor Vasa. 2012;54(11–12): e433–8.
  12. Liu S, Luo J, Zhang T, Zhang D, Zhang H. The combined role of obesity and depressive symptoms in the association with ischaemic heart disease and its subtypes. Sci Rep. 2022;12(1):14419.
  13. Logue J, Murray HM, Welsh P, Shepherd J, Packard C, Macfarlane P, et al. Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart. 2011; 97(7):564–8.
  14. Lau DCW, Dhillon B, Yan H, Szmítko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5):H2031-41.
  15. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399–409.
  16. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2): 115–26.

© 2023 Patil and Gond; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:  
<https://www.sdiarticle5.com/review-history/99493>*